Long-term survival with allogeneic stem cell transplant and donor lymphocyte infusion following salvage therapy with anti-CD52 monoclonal antibody (Campath) in a patient with α/β hepatosplenic T-cell non-Hodgkin's lymphoma

Asher Chanan-Khan, Tariq Islam, Arif Alam, Kena C. Miller, John Gibbs, Maurice Barcos, Myron S. Czuczman, Pamela Paplham, Theresa Hahn, Philip McCarthy

Research output: Contribution to journalArticle

24 Scopus citations


Hepatosplenic T-cell non-Hodgkin's lymphoma (HSTCL) is a rare, aggressive form of NHL, with a median survival of approximately 8 months. We were able to successfully induce complete remission in a patient with α/β HSTCL who was refractory to multiple prior chemotherapy regimens, using the humanized anti-CD52 monoclonal antibody alemtuzumab (Campath®). Once disease was controlled, the patient was able to undergo allogeneic stem cell transplantation (SCT), which resulted in complete remission. Furthermore, upon relapse, we were able to re-induce complete clinical and molecular remission with donor lymphocyte infusions. At Day 655 (post-SCT), the patient remains in complete remission. These data suggest a potential role for alemtuzumab and allogeneic SCT in the treatment of T-cell NHL.

Original languageEnglish (US)
Pages (from-to)1673-1675
Number of pages3
JournalLeukemia and Lymphoma
Issue number8
StatePublished - Aug 1 2004



  • Alemtuzumab
  • Allogeneic
  • Non-Hodgkin's lymphoma
  • T-cell

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this